Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 13Triple Negative Breast Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3NSCLC 2Endometrial Neoplasms 2Breast Neoplasms 2Advanced Solid Tumors 2Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Hodgkin Disease 1HER2-positive Colorectal Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Esophageal Neoplasms 1Colorectal Cancer Metastatic 1Burkitt Lymphoma 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumor 1Advanced Malignancies 1Advanced Colorectal Cancer 1

Interventions

Rituximab 101Cyclophosphamide 51Prednisone 32Doxorubicin 32Vincristine 31Gemcitabine 29Lenalidomide 27Oxaliplatin 22Bendamustine Hydrochloride 19ibrutinib 16fludarabine 16tafasitamab 12polatuzumab vedotin 12venetoclax 11tisagenlecleucel 11obinutuzumab 11loncastuximab tesirine 9Etoposide 9zanubrutinib 8Prednisolone 8Injections 8Ifosfamide 8Carboplatin 8selinexor 7pembrolizumab 7durvalumab 7axicabtagene ciloleucel 7Dexamethasone 7tazemetostat 6parsaclisib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Large B-Cell, Diffuse × HMPL-013 × Clear all
NCT05565417 2025-10-16

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Immunitas Therapeutics

Phase 1/2 Active not recruiting
67 enrolled
BreastGastrointestinalHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡